Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Abnormalities in neurotrophic systems have been reported in Alzheimer's disease (AD), as shown by decreased serum brain-derived neurotrophic factor (BDNF) levels and association with BDNF genetic polymorphisms. In this study, we investigate whether these findings can be detected in patients with mild cognitive impairment (MCI), which is recognized as a high risk condition for AD. We also address the impact of these variables on the progression of cognitive deficits within the MCI-AD continuum. METHODS: One hundred and sixty older adults with varying degrees of cognitive impairment (30 patients with AD, 71 with MCI, and 59 healthy controls) were longitudinally assessed for up to 60 months. Baseline serum BDNF levels were determined by sandwich ELISA, and the presence of polymorphisms of BDNF and apolipoprotein E (Val66Met and APOE*E4, respectively) was determined by allelic discrimination analysis on real time PCR. Modifications of cognitive state were ascertained for non-demented subjects. RESULTS: Mean serum BDNF levels were reduced in patients with MCI and AD, as compared to controls (509.2+/-210.5; 581.9+/-379.4; and 777.5+/-467.8 pg/l respectively; P<0.001). Baseline serum BDNF levels were not associated with the progression of cognitive impairment upon follow-up in patients with MCI (progressive MCI, 750.8+/-463.0; stable MCI, 724.0+/-343.4; P=0.8), nor with the conversion to AD. Although Val66Met polymorphisms were not associated with the cross-sectional diagnoses of MCI or AD, the presence of Met-BDNF allele was associated with a higher risk of disease-progression in patients with MCI (OR=3.0 CI(95%) [1.2-7.8], P=0.02). We also found a significant interaction between the APOE*E4 and Met-BDNF allele increasing the risk of progression of cognitive impairment in MCI patients (OR=4.4 CI(95%) [1.6-12.1], P=0.004). CONCLUSION: Decreased neurotrophic support, as indicated by a reduced systemic availability of BDNF, may play role in the neurodegenerative processes that underlie the continuum from MCI to AD. The presence of Met-BDNF allele, particularly in association with APOE*E4, may predict a worse cognitive outcome in patients with MCI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Roth, M., Tym, E., Mountjoy, C. Q., Huppert, F. A., Hendrie, H., Verma, S., & Goddard, R. (1986) · British Journal of Psychiatry · doi:10.1192/bjp.149.6.698 · Cited by 2,090 · cited 1×
“In brief, all participants underwent a comprehensive clinical and cognitive evaluation including the administration of the CAMDEX semi-structured interview (Roth et al. 1986), which yields a cognitive sub-scale (CAMCOG), the Mini-Mental State Examination (Folstein et al. 1975).”
BackgroundTransport of brain-derived neurotrophic factor across the blood–brain barrier
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., & Kastin, A. J. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00141-5 · Cited by 1,354
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., Wang, L., Blesch, A., Kim, A., Conner, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1912 · Cited by 1,034 · cited 1×
“Finally, in aged primates, there is evidence that BDNF may reverse neuronal atrophy and ameliorate age-related cognitive decline (Nagahara et al. 2009).”
BackgroundPeng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691
Chételat, G., Landeau, B., Eustache, F., Mézenge, F., Viader, F., de la Sayette, V., Desgranges, B., & Baron, J.-C. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.05.015 · Cited by 526 · cited 1×
“…Met-BDNF and APOE ∗ 4 alleles were associated with the progression of brain atrophy in healthy elderly controls and in patients with MCI (Nemoto et al. 2006; Hashimoto et al. 2009), in a pattern similar to that found in MCI patients who convert to AD (Chételat et al. 2005; Davatzikos et al. 2009).”
ResultVascular endothelial cells synthesize and secrete brain‐derived neurotrophic factor
Nakahashi, T., Fujimura, H., Altar, C. A., Li, J., Kambayashi, J.-I., Tandon, N. N., & Sun, B. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01302-8 · Cited by 430 · cited 1×
“The cellular sources of BDNF found in the human plasma are not yet clearly defi ned; potential sources are the vascular endothelial and smooth muscle cells (Nakahashi et al. 2000).”
BackgroundDavatzikos, C., Xu, F., An, Y., Fan, Y., & Resnick, S. M. (2009) · Brain · doi:10.1093/brain/awp091 · Cited by 315
Scalzo, P., Kümmer, A., Bretas, T. L., Cardoso, F., & Teixeira, A. L. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5357-2 · Cited by 299 · cited 2×
“In fact, several studies have demonstrated that serum BDNF levels are reduced in many neurobiologically distinct conditions that are associated with cognitive defi cits, such as late-life depression, bipolar disorder and Parkinson disease (Cunha et al. 2006; de Oliveira et al. 2009; Diniz et al. 2010; Scalzo et al. 20…”
BackgroundSelf-citation
Cited by
Miranda, M., Morici, J. F., Zanoni, M. B., & Bekinschtein, P. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00363 · Cited by 1,416
Brain-Derived Neurotrophic Factor in Alzheimer’s Disease and Its Pharmaceutical Potential
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00279-0 · Cited by 606
The role of CREB and BDNF in neurobiology and treatment of Alzheimer's disease
Amidfar, M., de Oliveira, J., Kucharska, E., Budni, J., & Kim, Y.-K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118020 · Cited by 410
The involvement of BDNF, NGF and GDNF in aging and Alzheimer's disease
Josiane, Tatiani, Francielle, Michelle, & Alexandra (2015) · Aging and disease · doi:10.14336/ad.2015.0825 · Cited by 407
Serum Brain-Derived Neurotrophic Factor and the Risk for Dementia: The Framingham Heart Study
Weinstein, G., Beiser, A. S., Choi, S. H., Preis, S. R., Chen, T. C., Vorgas, D., Au, R., Pikula, A., Wolf, P. A., DeStefano, A. L., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.4781 · Cited by 289
“Prevalent cardiovascular disease 192 (23) 255 (20) .”
Background
Metadata
- Authors
- Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Ojopi, E. B., Talib, L. L., Mendonça, V. A., Izzo, G., & Gattaz, W. F.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2010-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 774-780
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2146787134
- Cited by
- 134
- References
- 9
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. https://app.cochat.ai/papers/10.3109/15622971003797241
- The paper
- Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Ojopi, E. B., Talib, L. L., Mendonça, V. A., Izzo, G., & Gattaz, W. F. (2010). Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. The World Journal of Biological Psychiatry. https://doi.org/10.3109/15622971003797241
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.